## Phylogeny  
MAPK7 (also called ERK5, BMK1 or PRKM7) is a mitogen-activated protein kinase that forms a distinct branch within the ERK group of the MAPK family. Orthologues are present in all vertebrates, underscoring strong evolutionary conservation (Nishimoto & Nishida, 2006). Divergence from other MAPKs was accompanied by acquisition of an extended C-terminal region that confers transcriptional-regulatory functions (Nithianandarajah-Jones et al., 2014; Lin et al., 2016).

## Reaction Catalyzed  
ATP + L-seryl/threonyl-[protein] ⇌ ADP + H⁺ + O-phospho-L-seryl/threonyl-[protein] (Cook et al., 2020).

## Cofactor Requirements  
Mg²⁺ is required for catalytic activity (Wang & Tournier, 2006).

## Substrate Specificity  
MAPK7 phosphorylates Ser/Thr residues within proline-directed motifs. Documented substrates include transcription factors (e.g., MEF2C) and regulatory proteins such as SGK1 at Ser-78 (Cook et al., 2020). Motif definition is incomplete but resembles other MAPKs with a preference for Pro at +1 (Nithianandarajah-Jones et al., 2014).

## Structure  
The 816-residue protein comprises:  
• N-terminal kinase domain (~1–406 aa) that shares 50–66 % identity with ERK1/2 and contains the TEY activation motif (Thr218-Glu-Tyr220), glycine-rich loop, C-helix and hydrophobic spine (Lin et al., 2016; Elkins et al., 2013).  
• C-terminal extension (~410 aa) harbouring a nuclear-localization signal and transcriptional-activation domain, enabling dual kinase/transcription-factor roles (Cook et al., 2020; Monti et al., 2022).  
X-ray structures of the kinase domain delineate an ATP-binding pocket with residues that dictate inhibitor selectivity (Elkins et al., 2013).

## Regulation  
Activation requires MAP2K5 (MEK5)-mediated phosphorylation of the TEY motif, relieving C-terminal autoinhibition and exposing the nuclear-localization signal (Lin et al., 2016; Lochhead et al., 2020). Additional regulation includes:  
• C-terminal autophosphorylation enhancing transcriptional activity (Cook et al., 2020).  
• Phosphorylation at Thr732 promoting nuclear accumulation (Honda et al., 2015).  
• Association with HSP90/CDC37 in the inactive state; growth-factor signals via receptor tyrosine kinases stimulate MEK5-dependent activation in a Ras-independent manner (Cook et al., 2020; Paudel et al., 2021).

## Function  
Upon activation, MAPK7 translocates to the nucleus to modulate gene expression required for cell proliferation, differentiation and survival. Key roles include:  
• Phosphorylation of MEF2C and SGK1 to drive growth-factor-induced cell-cycle progression (Cook et al., 2020; Drew et al., 2012).  
• Anti-apoptotic effects in cardiomyocytes via STUB1/CHIP-mediated degradation of ICER isoforms (information cited in Nomenclature).  
• Maintenance of endothelial integrity and vascular homeostasis (Lochhead et al., 2012; Nithianandarajah-Jones et al., 2014).

## Inhibitors  
Several ATP-competitive small molecules (e.g., benzo[e]pyrimido[5,4-b][1,4]diazepin-6(11H)-ones) inhibit MAPK7, yet some compounds paradoxically activate MAPK7 signalling (Cook et al., 2020; Lochhead et al., 2020; Miller et al., 2023).

## Other Comments  
Over-expression or hyperactivation of MAPK7 is observed in multiple cancers (breast, prostate, hepatocellular, pancreatic) where it supports tumour growth, angiogenesis and metastasis. Dysregulation typically arises from gene amplification or aberrant phosphorylation rather than recurrent point mutations (Monti et al., 2022; Drew et al., 2012).

## 9. References  
Cook, S. J., Tucker, J. A., & Lochhead, P. A. (2020). Small molecule ERK5 kinase inhibitors paradoxically activate ERK5 signalling: Be careful what you wish for…. Biochemical Society Transactions, 48, 1859–1875. https://doi.org/10.1042/BST20190338  

Drew, B. A., Burow, M. E., & Beckman, B. S. (2012). MEK5/ERK5 pathway: The first fifteen years. Biochimica et Biophysica Acta (BBA) – Reviews on Cancer, 1825, 37–48. https://doi.org/10.1016/j.bbcan.2011.10.002  

Elkins, J. M., Wang, J., Deng, X., Pattison, M. J., Arthur, J. S. C., Erazo, T., Gomez, N., Lizcano, J. M., Gray, N. S., & Knapp, S. (2013). X-ray crystal structure of ERK5 (MAPK7) in complex with a specific inhibitor. Journal of Medicinal Chemistry, 56, 4413–4421. https://doi.org/10.1021/jm4000837  

Honda, T., Obara, Y., Yamauchi, A., Couvillon, A. D., Mason, J. J., Ishii, K., & Nakahata, N. (2015). Phosphorylation of ERK5 on Thr732 is associated with ERK5 nuclear localization and ERK5-dependent transcription. PLOS ONE, 10, e0117914. https://doi.org/10.1371/journal.pone.0117914  

Lin, E. C. K., Amantea, C. M., Nomanbhoy, T. K., Weissig, H., Ishiyama, J., Hu, Y., Sidique, S., Li, B., Kozarich, J. W., & Rosenblum, J. S. (2016). ERK5 kinase activity is dispensable for cellular immune response and proliferation. Proceedings of the National Academy of Sciences, 113, 11865–11870. https://doi.org/10.1073/pnas.1609019113  

Lochhead, P. A., Gilley, R., & Cook, S. J. (2012). ERK5 and its role in tumour development. Biochemical Society Transactions, 40, 251–256. https://doi.org/10.1042/BST20110663  

Lochhead, P. A., Tucker, J. A., Tatum, N. J., Wang, J., Oxley, D., Kidger, A. M., Johnson, V. P., Cassidy, M. A., Gray, N. S., Noble, M. E. M., & Cook, S. J. (2020). Paradoxical activation of the protein kinase-transcription factor ERK5 by ERK5 kinase inhibitors. Nature Communications, 11, 1383. https://doi.org/10.1038/s41467-020-15031-3  

Miller, D. C., Harnor, S. J., Martin, M. P., Noble, R. A., Wedge, S. R., & Cano, C. (2023). Modulation of ERK5 activity as a therapeutic anti-cancer strategy. Journal of Medicinal Chemistry, 66, 4491–4502. https://doi.org/10.1021/acs.jmedchem.3c00072  

Monti, M., Celli, J., Missale, F., Cersosimo, F., Russo, M., Belloni, E., Di Matteo, A., Lonardi, S., Vermi, W., Ghigna, C., & Giurisato, E. (2022). Clinical significance and regulation of ERK5 expression and function in cancer. Cancers, 14, 348. https://doi.org/10.3390/cancers14020348  

Nishimoto, S., & Nishida, E. (2006). MAPK signalling: ERK5 versus ERK1/2. EMBO Reports, 7, 782–786. https://doi.org/10.1038/sj.embor.7400755  

Nithianandarajah-Jones, G. N., Wilm, B., Goldring, C. E. P., Müller, J., & Cross, M. J. (2014). The role of ERK5 in endothelial cell function. Biochemical Society Transactions, 42, 1584–1589. https://doi.org/10.1042/BST20140276  

Paudel, R., Fusi, L., & Schmidt, M. (2021). The MEK5/ERK5 pathway in health and disease. International Journal of Molecular Sciences, 22, 7594. https://doi.org/10.3390/ijms22147594  

Roberts, O. L., Holmes, K., Müller, J., Cross, D. A. E., & Cross, M. J. (2009). ERK5 and the regulation of endothelial cell function. Biochemical Society Transactions, 37, 1254–1259. https://doi.org/10.1042/BST0371254  

Stecca, B., & Rovida, E. (2019). Impact of ERK5 on the hallmarks of cancer. International Journal of Molecular Sciences, 20, 1426. https://doi.org/10.3390/ijms20061426  

Wang, X., & Tournier, C. (2006). Regulation of cellular functions by the ERK5 signalling pathway. Cellular Signalling, 18, 753–760. https://doi.org/10.1016/j.cellsig.2005.11.003